Previous Article | Next Article 
Journal of Virology, August 1999, p. 7001-7007, Vol. 73, No. 8
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Tamplicon-7, a Novel T-Lymphotropic Vector Derived
from Human Herpesvirus 7
Hila
Romi,
Oded
Singer,
Debora
Rapaport, and
Niza
Frenkel*
Laboratory for Molecular Virology, Department
of Cell Research and Immunology, Tel Aviv University, Tel-Aviv
69978, Israel
Received 11 December 1998/Accepted 23 April 1999
 |
ABSTRACT |
We describe the derivation of a novel T-cell-defective virus vector
employing the human herpesvirus 7 (HHV-7). The new vector, designated
Tamplicon-7, replicates in CD4+ T cells. The system is
composed of a helper virus and defective virus genomes derived by the
replication of the input Tamplicon vector. There are two
cis-acting functions required for the replication and
packaging of the defective virus genomes in the presence of the helper
virus: the viral DNA replication origin and the composite cleavage and
packaging signal, which directs the cleavage and packaging of defective
virus genomes. Viral DNA replication is compatible with the rolling
circle mechanism, producing large head-to-tail concatemers of the
Tamplicon vector. Thus, in the presence of the helper virus, the
replicated vectors are packaged and secreted into the medium.
Furthermore, we have shown that the vector can be employed to express a
foreign gene, encoding the green fluorescent protein, in the T cells
infected with the HHV-7 helper virus. We predict that the Tamplicon-7
vector might be potentially useful for gene therapy of diseases
affecting the human CD4+ T cells, including autoimmune
diseases, T-cell lymphomas, and AIDS.
 |
TEXT |
Human herpesvirus 7 (HHV-7) was
initially isolated in our laboratory from activated CD4+ T
cells purified from the peripheral blood of a healthy 26-year-old individual (strain RK) (10). It has been found to be a
ubiquitous virus which infects the majority of children when they are 3 to 6 years old (17, 34). The virus then becomes latent in
peripheral blood mononuclear cells. It has been suggested that HHV-7
may cause roseola infantum (or exanthem subitum). Although HHV-7 was isolated from a roseola infantum patient (30), the vast
majority of exanthem subitum isolates correspond to HHV-6 (36,
37), and it is possible that the virus was indirectly associated
with the disease. Specifically, primary HHV-7 infections were found to
result in a simultaneous increase of HHV-6 antibody titers, most likely
reflecting the reactivation of HHV-6 from latency in peripheral blood
mononuclear cells (16). It has been suggested that the
reactivated HHV-6B could cause roseola infantum (16). Thus
far, there is no disease known to be directly associated with HHV-7.
Additionally, the virus can be found in the saliva of more than 80% of
healthy individuals (3, 15, 35).
Latent HHV-7 can be induced to begin replication in vitro by T-cell
activation (2, 10, 11, 16). It has been shown that the CD4
marker is a critical component of the HHV-7 receptor (20).
This, most likely, is the basis for targeting CD4+ cells,
although further analyses are required to determine that no other
receptor(s) can mediate viral adsorption and entry. Also, the virus has
been found to interfere with human immunodeficiency virus
(20). Furthermore, it has recently been shown that HHV-7 could compete with human immunodeficiency virus type 1 in macrophages also carrying the CD4 surface moiety (4).
The entire HHV-7 DNA has been sequenced, including the JI and,
recently, RK strains (22, 24). Reassessment of the genetic content of HHV-7 has indicated that the HHV-7 genome contains 84 different genes. The organization of the viral genes appears to be
similar to the corresponding arrangements of HHV-6 genes. Fragments of
HHV-7 were determined to have 50 to 60% nucleotide sequence similarity
to those of HHV-6 DNA (22, 24, 27).
The construction of the Tamplicon-7 vector was based on aspects of
viral DNA replication and packaging. Specifically, the HHV-7 genome is
a linear molecule of 150 kb composed of a long unique DNA sequence (U)
of 133 kb flanked by direct repeats (DRs) DRL and
DRR and arranged as DRL-U-DRR
(25, 27). This resembles the DNA structures of HHV-6
(14, 19, 21), the channel catfish virus (5), and
equine herpesvirus 2 (31). The DRs range in size from 6 to
12 kb in different HHV-7 strains (27a). HHV-7 DNA
replication is compatible with the rolling circle mechanism, producing
large concatemeric genomes which are cleaved approximately a genome
length apart, as determined by the locations of the DR elements. The
exact cleavage sites are strictly determined by the
nucleotide-measuring functions of the pac-1 and pac-2 signals (6; for a review, see reference
13). The DR elements within the HHV-7 genome are
bound by the pac-1 and pac-2 signals, which determine the sites for the
cleavage of replicated viral DNA. Cleavage occurs 44 and 33 bp from the
pac-1 and pac-2 signals of HHV-7, respectively. The resulting cleaved
DNA is packaged as has been shown for herpes simplex virus (HSV) and
other herpesviruses (6, for a review, see reference
13). Additional units within the DR elements of
HHV-7 and HHV-6 are telomeric-type reiterations featuring GGGTTA
or other variations, which are reiterated various numbers of
times in different viral strains (26, 27a, 32).
The Tamplicon-7 vector system.
The defective HHV-7 vector
system was designated Tamplicon-7 to delineate the capability of the
vector to replicate in T cells. The system has features similar to
those of the HSV vector amplicon (12, 18, 29). Specifically,
the Tamplicon-7 system consists of a mixture of helper virus and
defective virus genomes generated from engineered Tamplicons. Two
cis-acting functions are required for the propagation of the
defective virus genomes in the presence of the helper virus: the viral
DNA replication origin (oriLyt) and the composite pac signal required
for the cleavage and packaging of the viral genome. The helper virus
contributes, in trans, the replication and packaging
machinery, such as DNA replication enzymes, packaging functions, and
the proteins and glycoproteins participating in the buildup of the
structural virions. The studies concerning the cis-acting
signals required for propagation of the defective genomes are briefly
summarized below.
HHV-7 oriLyt.
The lytic replication origin, oriLyt, of HHV-6
DNA was identified in HHV-6B(Z29) by Dewhurst and coworkers
(7). Figure 1 displays the
localization of the DNA replication origin of HHV-7(RK). Based on the
alignment of the HHV-6A(U1102) and the HHV-7(JI) nucleotide sequences,
we estimated that the oriLyt of HHV-7(RK) is located in the region
between the major DNA binding protein (U41) and the conserved
herpesvirus transactivator (U42). To obtain a functional replication
origin, cytoplasmic DNA was prepared from Sup-T1 cells (1,
28) which were infected with HHV-7(RK), and a cloned library of
BsrFI-cleaved DNA was derived. From the generated clones, a
1.9-kb clone (pNF1166) was found to contain the putative viral DNA
replication origin. Furthermore, as shown below, a 1-kb subclone,
pNF1168, was shown to replicate efficiently in helper virus-infected
cells.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 1.
Cloning of oriLyt of HHV-7(RK). Virion DNA was extracted
from the cytoplasmic fraction of HHV-7(RK)-infected Sup-T1 cells and
was used to generate a cloned library. BsrFI-cleaved viral
DNA fragments were cloned into a dephosphorylated Bluescript plasmid
previously cleaved with XmaI. (a) In order to identify
colonies containing the expected 1.9-kb BsrfI insert, the
library was screened with the two PCR primers RH1
(5'-CCGAAACAACAGTTTCATTATC-3') and RH3
(5'-AAAGAAGTTGATTCTATAGATTTTGAA-3'). The primers were
synthesized from the two open reading frames flanking the putative
location of HHV-7 oriLyt (orf U41, a major DNA binding protein, and orf
U42, a herpesvirus-transactivating protein). Taq DNA
polymerase (AB) and Taq extender (Stratagene) were used, and
30 cycles of amplification were performed under the following
conditions: 94°C for 1 min, 59°C for 1 min, and 72°C for 1 min.
PCR was performed on all the colonies, and positive colonies showed a
specific 700-bp PCR product. (b) One of the positive clones (pNF1166)
was cleaved with HpaI and BpmI, and after
blunting of the BpmI site, a 1-kb fragment was cloned into
the EcoRV site of a Bluescript plasmid, yielding pNF1168.
Shown are map coordinates, in kilobases, for the positions of clones
and primers that were used.
|
|
HHV-7 oriLyt replication operates by rolling circle mechanism,
generating large concatemers of replicated DNA.
To test the
replication ability of pNF1168, 107 Sup-T1 cells were
infected for 7 days with the helper virus HHV-7(RK). The infected cells
were then exposed to electroporation with the pNF1168 clone by using a
Bio-Rad gene pulser at 300 V and 960 µF in 0.8 ml of
phosphate-buffered saline (PBS) without Ca2+ and
Mg2+. One week later, the culture was harvested and the
total cell DNA, prepared as previously described (8), was
digested with DpnI in order to discriminate between
replicated viral DNA and the unreplicated input plasmid DNA.
DpnI cleaves methylated dam-type (GATC) DNA that
has replicated in bacteria but not unmethylated DNA that has replicated
in animal cells. As seen in Fig. 2, the cells contained large concatemeric DpnI-resistant DNA
molecules, which represented the replication progeny of the input
oriLyt plasmid. Specifically, the DpnI-resistant replication
product consisted of high-molecular-weight concatemeric DNA (Fig. 2,
lane 2) that, upon partial digestion with XhoI (lanes 3 to
8), could be converted into a ladder of DNA fragments with sizes
representing multimers of the linear pNF1168 clone. Full
XhoI digestion resulted in the complete conversion of such
multimeric products into unit-length molecules (Fig. 2, lane 9). We
have concluded that the 1-kb segment contained a functional replication
origin that operates by the rolling circle mechanism. It is noteworthy
that at the time we analyzed the oriLyt of HHV-7(RK), van Loon et al.
(33) identified the location of oriLyt of HHV-7 (strain R-2)
in a PCR product.

View larger version (61K):
[in this window]
[in a new window]
|
FIG. 2.
Transient-replication assay of oriLyt. The mechanism of
replication of the 1-kb oriLyt construct (pNF1168) was shown to be
compatible with the rolling circle mechanism. In lanes 2 through 9, DNAs were cleaved overnight with DpnI and partially digested
with XhoI (7 U per sample). In lane 10, the DNA was cleaved
overnight with DpnI and BglII to verify that the
plasmid did not replicate by integrating into the viral genome. There
are no BglII sites in the construct but there are several
sites in the HHV-7 genome. As seen in lane 10, the
high-molecular-weight DNA was not cleaved by BglII. As the
negative control, 107 uninfected Sup-T1 cells were
transfected with pNF1168, and the extracted DNA was digested overnight
with DpnI and XhoI (lane 11). Southern blot
hybridizations were performed with a nonradioactive
digoxigenin-dUTP-labeled Bluescript probe DNA (Boehringer Mannheim).
Shown are the positions of the partially digested concatemeric DNA
(arrowheads) and the times of XhoI digestion. A time of 0 min corresponds to a sample taken before the addition of
XhoI. Numbers on the sides are molecular sizes, in
kilobases.
|
|
The cleavage and packaging signal of HHV-7.
As outlined above,
the pac-1 and pac-2 signals of HHV-7(RK) are located within the DR
segments several kilobases away from each other. The circularization of
the viral genome followed by DNA replication creates viral DNA
concatemers with pac-1 and pac-2 properly oriented for measurement and
cleavage. As shown in Fig. 3a, the PCR
amplification of HHV-7(RK) employing pac-1 and pac-2 sequences as
primers yielded a segment of 170 bp which was cloned and sequenced as
displayed in Fig. 3b, which also shows its homology to HHV-7(JI). As
shown in Fig. 3c, the arrangement of the conserved pac-1 and pac-2
motifs and their proximities to the genomic termini are consistent with
those found in other herpesviruses (13). In consequence,
cleavage was estimated to be 44 bp from the pac-1 element and 33 bp
from the pac-2 element of HHV-7(RK), as is the case in HSV-1(F),
HHV-6A(U1102), HHV-6B(Z29), and HHV-7(JI).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 3.
Cleavage and packaging signal of HHV-7. (a) Location of
the primers (H7TER2 and H7TER1) used to amplify the
DRR-DRL junction. The sequences of the primers
were taken from the work of Secchiero et al. (26). (b)
HHV-7(RK) total DNA was used as a template for PCR amplification with
the H7TER2 and H7TER1 primers (26). The 170-bp PCR product
was cloned and sequenced and compared to the complete sequence of
HHV-7(JI). The conserved sequence elements of pac-1 and pac-2 are
boxed. The sequences of the primers are underlined by arrows. (c) Pac-1
and pac-2 sequence homologues are shown for HSV-1(F), HHV-6A(U1102),
HHV-6B(Z29), HHV-7(JI), and HHV-7(RK) (22-24, 32).
|
|
Generation of the constructed Tamplicon-7 vector.
Employing
the 1-kb oriLyt segment in pNF1168 and the 170-bp pac segment in
pNF1181, we produced the Tamplicon-7 vector in pNF1182, a vector
capable of replicating in T cells. The three clones are schematically
displayed in Fig. 4a.

View larger version (49K):
[in this window]
[in a new window]
|
FIG. 4.
The Tamplicon-7 vector system. (a) Derivation of the
HHV-7 Tamplicon. The 1-kb oriLyt fragment was excised from pOrilyt
(pNF1168) by digestion with SmaI and HindIII.
The fragment was ligated to the HindIII and
HincII sites of pNF1181 that contained the 170-bp pac
fragment. The resulting plasmid that contained both elements was
designated Tamplicon-7 (pNF1182). The 1.6-kb GFP gene was excised from
the pEGFP plasmid (Clontech) and ligated to pNF1182 between the
BamHI and PstI sites. The resulting plasmid was
designated Tamplicon-7.GFP (pNF1196). Shown are restriction enzyme
sites for EcoRV (EV), SmaI (Sma),
HindIII (H), HincII (HcII), BamHI
(B), and PstI (P). (b) Schematic structure of the packaged
HHV-7 helper virus and the packaged defective Tamplicon-7. (c)
Packaging assay of Tamplicon-7. Two independent infected cultures were
electroporated with Tamplicon-7 and a third culture was electroporated
with pOrilyt-7. Nuclear (nuc) and cytoplasmic (cyto) DNA preparations
and DNA from purified virions prepared from the medium (med.) were
extracted from all three cultures, digested with XhoI and
DpnI, and hybridized as previously described (lanes 2 to 9).
Lanes 1 and 10 contained a 1-kb DNA marker (M).
|
|
To test the constructed Tamplicon-7 vector system, Sup-T1 cells were
infected for 7 days with HHV-7(RK) helper virus until
infection was
clearly apparent. The infected cells were then exposed
to
electroporation with plasmids containing oriLyt or the Tamplicon-7
construct. Seven days later, the cells were harvested and fractionated
into the cytoplasmic and nuclear fractions as previously described
(
27). Briefly, the infected cells were treated with 0.6%
Nonidet
P-40 and Dounce homogenized, and the nuclei and cytoplasmic
fractions
were separated by centrifugation. To prepare the packaged
DNA,
0.5% sodium deoxycholate, DNase I (50 µg/ml), and RNase (10 µg/ml)
(all from Sigma) were added to the cytoplasmic fraction. In
addition,
purified virions were obtained from the medium of the
infected
cultures. The medium of infected cells was cleared of cells
and
cell debris by low-speed centrifugation (10 min, 3,000 rpm)
followed
by filtration through 0.4-µm-pore-size sterile disposable
syringe
filters (Corning). The filtered cell-free medium was
centrifuged
in a Beckman ultracentrifuge with a SW28 rotor (25,000 rpm,
3
h, and 4°C). The concentrated virions were digested with DNase
I, and then the packaged DNA was extracted. All the DNA samples
were
digested overnight with
DpnI and
XhoI and were
hybridized
as previously
described.
The results shown in Fig.
4c can be summarized as follows. (i) The
Tamplicon-7 and oriLyt-7 plasmid DNAs were replicated in
the Sup-T1
nuclear fraction (Fig.
4, lanes 2 to 4). Both types
of plasmids yielded
replicated DNA that was
DpnI resistant. (ii)
Analyses of the
cytoplasmic DNA fractions revealed that Tamplicon-7
DNA was protected
from DNase digestion (lanes 5 and 6). No DNase-protected
DNA of the
oriLyt-7 construct was recovered from the cytoplasm
(lane 7). Thus, as
expected, the cleavage and packaging signal
present in the Tamplicon-7
was required for the transport of the
replicated and encapsidated DNA
into the cytoplasmic fraction.
(iii) Tamplicon-7 DNA molecules were
also recovered from the purified
virion samples obtained from the
medium (lane 9). Thus, in the
presence of helper virus, the Tamplicon-7
vector was secreted
into the medium as packaged in DNase-protected
particles, enabling
its further utilization as infectious virus. (iv)
In addition,
we prepared a chimera construct containing the HHV-6B(Z29)
oriLyt
and the HHV-7(RK) 170-bp pac segment. In the presence of
HHV-6A(U1102)
helper virus, this construct was found to be packaged
(data not
shown). The reciprocal chimera construct containing the
HHV-7(RK)
oriLyt and a cloned pac segment of HHV-6A(U1102)
(
27a), was also
packaged in the presence of HHV-7(RK) helper
virus (data not
shown).
Expression of the GFP in Sup-T1 T cells.
To test whether the
Tamplicon-7 system can be employed for gene transfer in T cells, we
inserted the 1.6-kb green fluorescent protein (GFP) gene (pEGFP;
Clontech) into the Tamplicon-7 vector (pNF1182). The GFP gene was
constructed with the cytomegalovirus promoter and the simian virus 40 polyadenylation signal. The generated construct, Tamplicon-7.GFP
(pNF1196 [Fig. 4a]), was tested for transfer and gene expression.
Specifically, Sup-T1 cells were exposed to electroporation with 15 pmol
of pNF1196 plasmid DNA under the conditions described above. After
24 h, the electroporated lymphocytes were mixed with equal numbers
of HHV-7(RK)-infected Sup-T1 cells and incubated for 7 days. To further
propagate the virus, the cultures were then mixed with uninfected
Sup-T1 cells (at a ratio of 1:4). After 7 days, 100-µl samples were
taken to test for GFP expression. The cells were washed with PBS,
resuspended in 20 µl of PBS, and dried on eight-well slides. Fixation
was done with a 3.7% formaldehyde solution and 100% cold acetone. A
slow-fade-antifade kit from Molecular Probes (Eugene, Oreg.) was
employed for mounting. The preparation was photographed by a Zeiss
Axioskop fluorescent microscope. Figure 5
shows the phase contrast of the infected Sup-T1 cells exposed with
fluorescence and of fluorescence exposure only. As can be seen in Fig.
5, GFP was expressed in the infected cells, most likely the cells which received both helper virus and the Tamplicon-7 vector virus (Fig. 5C
and D).

View larger version (74K):
[in this window]
[in a new window]
|
FIG. 5.
GFP expression of Tamplicon-7.GFP vector in Sup-T1
cells. Sup-T1 cells with the plasmid pNF1196 and the HHV-7(RK) helper
virus were photographed in a fluorescent microscope. (A, C, and E)
Phase-contrast exposure combined with fluorescence; (B, D, and F)
fluorescence exposure. Magnifications, ×270 (A, B, C, and D) and ×135
(E and F).
|
|
Potential use of the Tamplicon-7 vector in gene therapy.
We
describe in this communication the establishment of a novel vector
system replicated in CD4+ T cells. Two attractive features
of the system are noteworthy with regard to the potential use of the
system for gene therapy. First, the host range of HHV-7 might be
limited to lymphocytes carrying the CD4 moiety, as the receptor for the
virus has been suggested to reside within this cell surface component
(20). It remains to be seen whether the CD4 moiety is the
sole virus-related receptor or whether viral adsorption and entry into
the cells might occur through interaction with a secondary,
as-yet-unidentified, type of receptor(s). It will be of special
interest to determine whether the vector will also target
CD4+ macrophages as does the parental HHV-7. Second, HHV-7
is probably not involved directly in any known disease, as is supported
by the fact that the virus is persistently present in the salivary glands of more than 80% of healthy individuals (15, 34,
35). Hence, the newly designated Tamplicon-7 vector is
potentially attractive for future use in gene therapy for diseases
afflicting the CD4+ T cells, such as autoimmunity, T-cell
lymphomas, and AIDS. Current studies in our laboratory are geared
towards developing a Tamplicon-7 vector system devoid of packaged
helper virus by constructing a helper virus which does not have the
packaging signal, potentially removing the ability of the helper virus
to become packaged. One possible solution would be to transfect Sup-T1
cells with HHV-7 DNA in combination with the Tamplicon-7 plasmid DNA.
This would produce, in the transfected cells, all the proteins needed
in trans for the production of infectious Tamplicon-7
particles. The cleavage and packaging sequences would be deleted from
the helper virus DNA prior to the transfection. A similar approach has
been performed by Fraefel et al. (9) for a defective virus amplicon-like system derived from HSV-1.
 |
ACKNOWLEDGMENTS |
This work was supported by grants from the Israel Cancer
Association, the United States Israel Binational Science Foundation, and the Ela Kodesz Institute for Research on Cancer Development and Prevention.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Laboratory for
Molecular Virology, Department of Cell Research and Immunology, Tel Aviv University, Tel Aviv 69978, Israel. Phone: 972-3-6407166. Fax:
972-3-6407165. E-mail: nfrenkel{at}post.tau.ac.il.
 |
REFERENCES |
| 1.
|
Berneman, Z. N.,
D. V. Ablashi,
G. Li,
M. Eger-Fletcher,
M. S. Reitz,
C. Hung,
I. Brus,
A. L. Komaoff, and R. C. Gallo.
1992.
Human herpesvirus 7 is a T-lymphotropic virus and is related to, but significantly different from, human herpesvirus 6 and human cytomegalovirus.
Proc. Natl. Acad. Sci. USA
89:10552-10556[Abstract/Free Full Text].
|
| 2.
|
Berneman, Z. N.,
R. C. Gallo,
D. V. Ablashi,
N. Frenkel,
G. Katsafanas,
B. Kramarsky, and I. Brus.
1992.
Human herpesvirus 7 (HHV-7) strain JI: independent confirmation of HHV-7.
J. Infect. Dis.
166:690-691[Medline].
|
| 3.
|
Black, J. B.,
N. Inoue,
K. Kite-Powell,
S. Zaki, and P. E. Pellett.
1993.
Frequent isolation of human herpesvirus 7 from saliva.
Virus Res.
29:91-98[Medline].
|
| 4.
|
Crowley, R. W.,
P. Secchiero,
D. Zella,
A. Cara,
R. C. Gallo, and P. Lusso.
1996.
Interference between human herpesvirus 7 and HIV-1 in mononuclear phagocytes.
J. Immunol.
156:2004-2008[Abstract].
|
| 5.
|
Davison, A. J.
1992.
Channel catfish virus: a new type of herpesvirus.
Virology
186:9-14[Medline].
|
| 6.
|
Deiss, L. P.,
J. Chou, and N. Frenkel.
1986.
Functional domains within the a sequence involved in the cleavage-packaging of herpes simplex virus DNA.
J. Virol.
59:605-618[Abstract/Free Full Text].
|
| 7.
|
Dewhurst, S.,
S. C. Dollard,
P. E. Pellett, and T. R. Dambaugh.
1993.
Identification of a lytic-phase origin of DNA replication in human herpesvirus 6B strain Z29.
J. Virol.
67:7680-7683[Abstract/Free Full Text].
|
| 8.
|
Di Luca, D.,
G. Katsafanas,
E. C. Schirmer,
N. Balachandran, and N. Frenkel.
1990.
The replication of viral and cellular DNA in human herpesvirus 6-infected cells.
Virology
175:199-210[Medline].
|
| 9.
|
Fraefel, C.,
S. Song,
F. Lim,
P. Lang,
L. Yu,
Y. Wang,
P. Wild, and A. I. Geller.
1996.
Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells.
J. Virol.
70:7190-7197[Abstract/Free Full Text].
|
| 10.
|
Frenkel, N.,
E. C. Schirmer,
L. S. Wyatt,
G. Katsafanas,
E. Roffman,
R. M. Danovich, and C. H. June.
1990.
Isolation of a new herpesvirus from human CD4+ T cell.
Proc. Natl. Acad. Sci. USA
87:748-752[Abstract/Free Full Text].
|
| 11.
|
Frenkel, N., and L. S. Wyatt.
1992.
HHV-6 and HHV-7 as exogenous agents in human lymphocytes.
Dev. Biol. Stand.
76:259-265[Medline].
|
| 12.
|
Frenkel, N.,
O. Singer, and A. D. Kwong.
1994.
Minireview: the herpes simplex virus amplicon a versatile defective virus vector.
Gene Ther.
1:S40-S46.
|
| 13.
|
Frenkel, N., and E. Roffman.
1996.
Human herpesvirus 7, p. 2609-2635.
In
B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven, Philadelphia, Pa.
|
| 14.
|
Gompels, U. A.,
J. Nicholas,
G. Lawrence,
M. Jones,
B. J. Thomson,
M. E. Martin,
S. Efstathiou,
M. Craxton, and H. A. Macaulay.
1995.
The DNA sequence of human herpesvirus-6: structure, coding content, and genome evolution.
Virology
209:29-51[Medline].
|
| 15.
|
Hidaka, Y.,
Y. Liu,
M. Yamamoto,
R. Mori,
C. Miyazaki,
K. Kusuhara,
K. Okada, and K. Oeda.
1993.
Frequent isolation of human herpesvirus 7 from saliva samples.
J. Med. Virol.
40:343-346[Medline].
|
| 16.
|
Katsafanas, G. C.,
E. C. Schirmer,
L. S. Wyatt, and N. Frenkel.
1996.
In vitro activation of human herpesvirus 6 and 7 from latency.
Proc. Natl. Acad. Sci. USA
93:9788-9792[Abstract/Free Full Text].
|
| 17.
|
Kositanont, U.,
C. Wasi,
N. Ekpatcha,
A. Poomchart,
S. Likanonsakul,
I. Suphanip,
K. Balachandra, and K. Yamanishi.
1995.
Seroprevalence of human herpesvirus 6 and 7 infections in the Thai population.
Asian Pac. J. Allergy Immunol.
13:151-157[Medline].
|
| 18.
|
Kwong, A., and N. Frenkel.
1995.
Biology of herpes simplex virus (HSV) defective viruses and development of the amplicon system, p. 25-42.
In
M. G. Kaplitt, and A. D. Loewy (ed.), Viral vectors. Gene therapy and neuroscience application. Academic Press, San Diego, Calif.
|
| 19.
|
Lindquester, G. J., and P. E. Pellett.
1991.
Properties of the human herpesvirus 6 strain Z29 genome: G + C content, length, and presence of variable-length directly repeated terminal sequence elements.
Virology
182:102-110[Medline].
|
| 20.
|
Lusso, P.,
P. Secchiero,
R. W. Crowley,
A. Garzino-Demo,
Z. N. Berneman, and R. C. Gallo.
1994.
CD4 is a critical component of the receptor for human herpesvirus 7: interference with human immunodeficiency virus.
Proc. Natl. Acad. Sci. USA
91:3872-3876[Abstract/Free Full Text].
|
| 21.
|
Martin, M. E. D.,
B. J. Thomson,
R. W. Honess,
M. A. Craxton,
U. A. Gompels,
M. Y. Liu,
E. Littler,
J. R. Arrand,
I. Teo, and M. D. Jones.
1991.
The genome of human herpesvirus 6: maps of unit-length and concatemeric genomes for nine restriction endonucleases.
J. Gen. Virol.
72:157-168[Abstract/Free Full Text].
|
| 22.
|
Megaw, A. G.,
D. Rapaport,
B. Avidor,
N. Frenkel, and A. J. Davison.
1998.
The DNA sequence of the RK strain of human herpesvirus 7.
Virology
244:119-132[Medline].
|
| 23.
|
Mocarski, E. S., and B. Roizman.
1982.
Structure and role of the herpes simplex virus DNA termini in inversion, circularization and generation of virion DNA.
Cell
31:89-97[Medline].
|
| 24.
|
Nicholas, J.
1996.
Determination and analysis of the complete nucleotide sequence of human herpesvirus 7.
J. Virol.
70:5975-5989[Abstract].
|
| 25.
|
Ruvolo, V. R.,
Z. Berneman,
P. Secchiero, and J. Nicholas.
1996.
Cloning, restriction endonuclease mapping and partial sequence analysis of the genome of human herpesvirus 7 strain JI.
J. Gen. Virol.
77:1901-1912[Abstract/Free Full Text].
|
| 26.
|
Secchiero, P.,
J. Nicholas,
H. Deng,
T. Xiaopeng,
N. van Loon,
V. R. Ruvolo,
Z. N. Berneman,
M. S. Reitz Jr, and S. Dewhurst.
1995.
Identification of human telomeric repeat motifs at the genome termini of human herpesvirus 7: structural analysis and heterogeneity.
J. Virol.
69:8041-8045[Abstract].
|
| 27.
|
Singer, O., and N. Frenkel.
1997.
Human herpesvirus 7 (HHV-7) DNA: analysis of clones spanning the entire genome.
Arch. Virol.
142:287-303[Medline].
|
| 27a.
| Singer, O., and N. Frenkel. Unpublished data.
|
| 28.
|
Smith, S. D.,
M. Shatsky,
P. S. Cohen,
R. Warnke,
M. P. Link, and B. E. Glader.
1984.
Monoclonal antibody and enzymatic profiles of human malignant T-lymphoid cells and derived cell lines.
Cancer Res.
44:5657-5660[Abstract/Free Full Text].
|
| 29.
|
Spaete, R. R., and N. Frenkel.
1982.
The herpes simplex virus amplicon: a new eucaryotic defective-virus cloning-amplifying vector.
Cell
30:295-304[Medline].
|
| 30.
|
Tanaka, K.,
T. Kondo,
S. Torigoe,
S. Okada,
T. Mukai, and K. Yamanishi.
1994.
Human herpesvirus 7: another causal agent for roseola (exanthem subitum).
J. Pediatr.
125:1-5[Medline].
|
| 31.
|
Telford, E. A. R.,
M. S. Watson,
H. C. Aird,
J. Perry, and A. J. Davison.
1995.
The DNA sequence of equine herpesvirus 2.
J. Mol. Biol.
249:520-528[Medline].
|
| 32.
|
Thomson, B. J.,
S. Dewhurst, and D. Gray.
1994.
Structure and heterogeneity of the a sequences of human herpesvirus 6 strain variants U1102 and Z29 and identification of human telomeric repeat sequences at the genomic termini.
J. Virol.
68:3007-3014[Abstract/Free Full Text].
|
| 33.
|
van Loon, N.,
C. Dykes,
H. Deng,
G. Dominguez,
J. Nicholas, and S. Dewhurst.
1997.
Identification and analysis of a lytic-phase origin of DNA replication in human herpesvirus 7.
J. Virol.
71:3279-3284[Abstract].
|
| 34.
|
Wyatt, L. S.,
W. J. Rodriguez,
N. Balachandran, and N. Frenkel.
1991.
Human herpesvirus 7: antigenic properties and prevalence in children and adults.
J. Virol.
65:6260-6265[Abstract/Free Full Text].
|
| 35.
|
Wyatt, L. S., and N. Frenkel.
1992.
Human herpesvirus 7 is a constitutive inhabitant of adult human saliva.
J. Virol.
66:3206-3209[Abstract/Free Full Text].
|
| 36.
|
Yamanishi, K.,
T. Okuno,
K. Shiraki,
M. Takahashi,
T. Kondo,
Y. Asano, and T. Kurata.
1988.
Identification of human herpesvirus-6 as a causal agent for exanthem subitum.
Lancet
i:1065-1067.
|
| 37.
|
Yamanishi, K.
1992.
Human herpesvirus 6.
Microbiol. Immunol.
36:551-561[Medline].
|
Journal of Virology, August 1999, p. 7001-7007, Vol. 73, No. 8
0022-538X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Borenstein, R., Frenkel, N.
(2009). Cloning human herpes virus 6A genome into bacterial artificial chromosomes and study of DNA replication intermediates. Proc. Natl. Acad. Sci. USA
106: 19138-19143
[Abstract]
[Full Text]
-
Borenstein, R., Singer, O., Moseri, A., Frenkel, N.
(2004). Use of Amplicon-6 Vectors Derived from Human Herpesvirus 6 for Efficient Expression of Membrane-Associated and -Secreted Proteins in T Cells. J. Virol.
78: 4730-4743
[Abstract]
[Full Text]
-
Krug, L. T., Inoue, N., Pellett, P. E.
(2001). Sequence Requirements for Interaction of Human Herpesvirus 7 Origin Binding Protein with the Origin of Lytic Replication. J. Virol.
75: 3925-3936
[Abstract]
[Full Text]